

Mélanie Caron

De: Kate Lee [REDACTED]
Envoyé: 12 août 2021 08:01
À: Mélanie Caron
Cc: [REDACTED]
Objet: Update

Avertissement automatisé : Ce courriel provient de l'extérieur de votre organisation. Ne cliquez pas sur les liens et les pièces jointes si vous ne reconnaissez pas l'expéditeur.

Bonjour Mélanie,

On behalf of Crohn's and Colitis Canada, thank you again for our previous discussions regarding Québec's biologics to biosimilars switch policy.

This is a very important issue for our community. There is still much education needed on the uniqueness and severity of inflammatory bowel disease:

- Getting to a medication that works can be a difficult and long journey for people living with Crohn's or colitis.
- Many people go through a process of trial and error before finding the treatment that works.
- These diseases are very individual and medications that work for one person, may not work for another. What works one day, may stop working in the future.
- There are limited treatment options available.
- Medications play an important role in allowing patients to live productive lives.

We are grateful for your willingness to listen to us and your response that you have asked INESSS to review our requests. Having said this, we believe we need to continue the two-way discussion to support Crohn's and colitis patients. For these reasons and more, we are asking the government to have patience in executing this policy.

As such we are beginning a campaign to highlight these concerns.

www.crohnetcolite.ca/patience

Given our discussions, we wanted to give you a heads up on our campaign. We are also requesting another meeting with you individually so we can discuss further.

We look forward to meeting.

Sincerely,
Kate



Kate Lee, PhD, MBA
Vice President, Research and Patient Programs
Crohn's and Colitis Canada
600 - 60 St. Clair Ave. E., Toronto ON M4T 1N5
T: 416-920-5035 x 214
Get Gutsy: [Learn](#) | [Volunteer](#) | [Donate](#)